ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

aflutinib

Also written as “Furmonertinib”, “Alflutinib” and “ASK120067”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis · Breast Neoplasms, led by 6 companies.

Drug pageAflutinib: every studyMany companies study it; this page follows only the 21 they lead. All 63 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Apr 12, 202121 company-led studies, 11 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Allist Pharmaceuticalsits history only114 open or runningphase 3since Apr 12, 2021Nov 21, 2016Dec 2026phase 3 · NCT04853342
Beijing Aosaikang Pharmaceuticalits history only41 open or runningphase 3since Oct 12, 2019Apr 10, 2018none ahead
ArriVent BioPharmaits history only33 open or runningphase 3since Oct 31, 2022Apr 6, 2022Feb 2029phase 3 · NCT07185997
Abbisko Cayman11 open or runningphase 2since Oct 30, 2024Oct 30, 2024Dec 30, 2027phase 2 · NCT06668103
Alphamab Oncologyits history only11 open or runningphase 1since Mar 5, 2025Mar 5, 2025Jun 30, 2028phase 1 · NCT06868732
MediLink Therapeutics (Suzhou)its history only11 open or runningphase 2since Sep 3, 2025Sep 3, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 30, 2024First study: phase 2 study in Non-Small Cell Lung Cancer With EGFR MutationFirst studyNCT06668103 · 54 planned · China

Ahead

  1. Dec 30, 2027Primary completion: phase 2 study in Non-Small Cell Lung Cancer With EGFR MutationNCT06668103

TargetBeta

EGFR →read by rule
“The mesylate salt form of alflutinib, an orally available selective inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, ”NCIt, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

The one study Abbisko Cayman leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06668103Non-Small Cell Lung Cancer With EGFR Mutation · China2RecruitingDec 30, 202754

How it is read

Names in the registry

  • “Furmonertinib”, 6 entries
  • “Alflutinib”, 3 entries
  • “ASK120067”, 3 entries
  • “Firmonertinib”, 2 entries
  • “Furmonertinib 160mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.